ALAPIS Α.Β.Ε.Ε.
Announcement.
ALAPIS SA announces the following:
1. Pursuant to the decision No K2-12461/28.12.2009 of the Ministry of Economy, Competitiveness and Shipping it was approved the merger of ?ALAPIS HOLDING, INDUSTRIAL AND COMMERCIAL SOCIΙTΙ ANONYME OF PHARMACEUTICAL AND ORGANIC PRODUCTS? with its fully (100%) subsidiary ?PNG GEROLYMANTOS HEALTH AND BEAUTY COMMERCIAL AND INDUSTRIAL SOCIETE ANONYME?, by absorption of the latter from the former according to the decisions of their Board of Directors as of 22.09.2009 and 23.11.2009 and the provisions of articles 68-78 of the C.L. 2190/1920 and articles 1-5 of L. 2166/1993.
2. ALAPIS SA acquired a 50% stake of GENESIS ILAC for the amount of euro 1.7 mil.
GENESIS ILAC pharmaceutical company was established in 2000 and its headquarters are at Istanbul. GENESIS ILAC product portfolio comprises of pharmaceutical and OTC products (Sinomarin, Basiscream, Pulvo, Septrin, Actiq, Rinopanteina, Predictor, Mentopin, Calcimed D3, Cevitthot and Denol) which are mainly distributed to pediatricians, otolaryngologists, general physicians, dermatologists and oncologists. The company currently employs approximately 70 people (mainly medical representatives), while in 2008 its turnover amounted to euro 8.2 mil. According to IMS data, the company ranked 61st out of 309 pharmaceutical companies, on the basis of its 2008 turnover.
3. SAMBROOK MED SA PHARMACEUTICAL COMPANY, a fully (100%) subsidiary of ALAPIS SA, acquired from SAMBROOK PHARMACEUTICALS SA for the amount of euro 75,000, SANDOZ?s pharmaceutical company business unit, concerning the production of generic pharmaceutical products and signed an agreement for the distribution and promotion of SANDOZ GMBH?s generic products in the therapeutic categories of cardiology, osteoporosis, stomach protection, diabetes and antibiotics. This is a strategic agreement for ALAPIS group, since it aims at enhancing market share and establishing the Group in the generics market.
4. ALAPIS SA acquired the remaining 40% of the subsidiary MEDIMEC SA that was held up to now by DILACO SA, a fully (100%) subsidiary of ALAPIS SA. ALAPIS SA now holds directly 100% of MEDIMEC.
The business activity of DILACO SA and SCALONITA LTD, a fully (100%) subsidiary of ALAPIS SA, was absorbed by PHARMACARE LTD, which is also a fully (100%) subsidiary of ALAPIS SA.
Finally, the absorption of the detergent and cosmetic products segment of DALL SA by ALAPIS SA was completed.
1. Pursuant to the decision No K2-12461/28.12.2009 of the Ministry of Economy, Competitiveness and Shipping it was approved the merger of ?ALAPIS HOLDING, INDUSTRIAL AND COMMERCIAL SOCIΙTΙ ANONYME OF PHARMACEUTICAL AND ORGANIC PRODUCTS? with its fully (100%) subsidiary ?PNG GEROLYMANTOS HEALTH AND BEAUTY COMMERCIAL AND INDUSTRIAL SOCIETE ANONYME?, by absorption of the latter from the former according to the decisions of their Board of Directors as of 22.09.2009 and 23.11.2009 and the provisions of articles 68-78 of the C.L. 2190/1920 and articles 1-5 of L. 2166/1993.
2. ALAPIS SA acquired a 50% stake of GENESIS ILAC for the amount of euro 1.7 mil.
GENESIS ILAC pharmaceutical company was established in 2000 and its headquarters are at Istanbul. GENESIS ILAC product portfolio comprises of pharmaceutical and OTC products (Sinomarin, Basiscream, Pulvo, Septrin, Actiq, Rinopanteina, Predictor, Mentopin, Calcimed D3, Cevitthot and Denol) which are mainly distributed to pediatricians, otolaryngologists, general physicians, dermatologists and oncologists. The company currently employs approximately 70 people (mainly medical representatives), while in 2008 its turnover amounted to euro 8.2 mil. According to IMS data, the company ranked 61st out of 309 pharmaceutical companies, on the basis of its 2008 turnover.
3. SAMBROOK MED SA PHARMACEUTICAL COMPANY, a fully (100%) subsidiary of ALAPIS SA, acquired from SAMBROOK PHARMACEUTICALS SA for the amount of euro 75,000, SANDOZ?s pharmaceutical company business unit, concerning the production of generic pharmaceutical products and signed an agreement for the distribution and promotion of SANDOZ GMBH?s generic products in the therapeutic categories of cardiology, osteoporosis, stomach protection, diabetes and antibiotics. This is a strategic agreement for ALAPIS group, since it aims at enhancing market share and establishing the Group in the generics market.
4. ALAPIS SA acquired the remaining 40% of the subsidiary MEDIMEC SA that was held up to now by DILACO SA, a fully (100%) subsidiary of ALAPIS SA. ALAPIS SA now holds directly 100% of MEDIMEC.
The business activity of DILACO SA and SCALONITA LTD, a fully (100%) subsidiary of ALAPIS SA, was absorbed by PHARMACARE LTD, which is also a fully (100%) subsidiary of ALAPIS SA.
Finally, the absorption of the detergent and cosmetic products segment of DALL SA by ALAPIS SA was completed.